Table 1:
Characteristics of included patients.
| Patient (n = 33) | |
|---|---|
| Age, years** | 65.1 ± 13.1 |
| Male sex, n (%) | 26 (78.8) |
| 1APACHE II** | 10.4 ± 6.83 |
| Charlson score** | 4.90 ± 2.8 |
| Urinary catheter | 16 (48.5) |
| UTI syndrome: | |
| - Cystitis | 24 (72.7) |
| - Pyelonephritis | 9 (27.3) |
| Positive blood cultures | 4 (12.1) |
| Clinical status: | |
| - Sepsis, n (%) | 10 (30.3) |
| - Shock, n (%) | 1 (3,0) |
| 2CMS daily dose (million IU)** | 5 ± 2.54 |
| CMS daily dose (in colistin base activity, (mg)/kg/day) | 2.21 ± 1.25 |
| 2CMS total cumulative dose (million IU)* | 24 (14.2–39.7) |
| 2CMS treatment duration, days** | 8.31 ± 6.43 |
| 3GFR at baseline (mL/min/1.73 m2)** | 100.2 ± 64.1 |
| Patients with 4CKD at baseline, n (%) | 8 (24.2) |
| 5Css,avg (mg/L)** | 1.19 ± 1.09 |
| 6AUC/MIC** | 60.5 ± 56.4 |
| fAUC/MIC** | 30.2 ± 28.2 |
| 6AUC/MIC ≥ 60 mg∙h/L, n (%) | 11 (33.3) |
| 5 % patients with Css,avg > 2.5 mg/L | 3 (9.1) |
| 7Expected Css, avg | 0.78 ± 0.07 |
| Css, avg above MIC | 22 (66.7) |
| Combined antibiotic therapy: | 14 (42.4) |
| - Meropenem | 6 (18.2) |
| - Amikacin | 3 (9.1) |
| - Ceftazidime | 5 (15.2) |
| 8AKI at the end of treatment, n (%) | 10 (30.3) |
| - R (Risk) | 3 (33.3) |
| - I (Injury) | 5 (55.5) |
| - F (Failure) | 2 (22.2) |
| Clinical cure, n (%) | 31 (93.9) |
| Microbiological follow up, n (%) | 23 (69.7) |
| Microbiological clearance, n (%) | 19/23 (82.6) |
*
Median (interquartile range).
**
Mean ± standard deviation.
1
APACHE II: Acute Physiology and Chronic Health Evaluation II.
2
CMS: colistin methanesulfonate
3
GFR: glomerular filtration rate
4
CKD: chronic kidney disease
5
Css,avg: colistin plasma concentration at steady-state
6
AUC: colistin area under the curve
7
Calculated Css,avg according the dosage algorithm of Nation et al
8
AKI: acute kidney injury.